Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

The agents that are available at present for the management of Alzheimer's disease treat only the symptoms of neurodegeneration and, at best, result in modest, short-term improvements in cognitive function. Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Neuroscience 2002-10, Vol.3 (10), p.824-828
1. Verfasser: Schenk, Dale
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The agents that are available at present for the management of Alzheimer's disease treat only the symptoms of neurodegeneration and, at best, result in modest, short-term improvements in cognitive function. Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic, and is an evolving approach to the treatment of Alzheimer's disease that offers a genuine opportunity to modify disease progression. Although initial clinical trials of one approach met with some setbacks, active or passive immunization holds great potential for treating or even preventing Alzheimer's disease.
ISSN:1471-003X
1471-0048
1471-0048
DOI:10.1038/nrn938